



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

**Complete if Known**

Application Number	10/729,795
Filing Date	December 5, 2003
First Named Inventor	Walters
Art Unit	1644
Examiner Name	Zachary S. Skelding
Attorney Docket Number	011823-012510US

Sheet	1	of	2
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**(Use as many sheets as necessary)**

Sheet

2

of

2

## Application Number

10/729,795

Filing Date

December 5, 2003

**First Named Inventor**

Walters

Art Unit

1644

Examiner Name

**Zachary S. Skelding**

Attorney Docket Number

011823-012510US

Examiner  
Initials \*Cite  
No. 1

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T<sup>2</sup>

/ Z S /

AA

CARPENTER et al., "A humanized non-FcR-binding antiCD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease," Blood, 99(8):2712-2719 (2002).

☐

/ ZS /

**AB**

HEAD et al., "Inflammatory Bowel Disease Part I: Ulcerative Colitis -- Pathophysiology and Conventional and Alternative Treatment Options.," Alternative Medicine Review, 8(3):247-283 (2003).

 $|ZS|$ 

AC

TUVLIN et al., "Novel therapies in the treatment of ulcerative colitis," *Expert Opin. Investig. Drugs*, 12(3):483-490 (2003).

☐Examiner  
Signature

/Zachary Skelding/

Date Considered

07/04/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.